Latest News
-
eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement
-
Generate Life Sciences Establishes Newborn Stem Cell Manufacturing Facility to Support the Development of Personalized Therapeutics
-
Cellares and Poseida Therapeutics Partner to Accelerate Cell Therapy Manufacturing
-
eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement
eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement
eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement Belgium-based eTheRNA immunotherapies has established a collaboration and licence agreement with Ghent University for mRNA delivery with enhanced thermostability, biodegradability and safety. eTheRNA will receive worldwide commercialisation rights for the new generation of lipid nanoparticle (LNP) formulations co-developed with the university’s research group […]
How thalassemia gene therapy approval is making a difference
Beta thalassemia is a hereditary blood disorder that affects a significant number of people across the world, predominantly in regions like the Middle East, Mediterranean countries, India, and Southeast Asia. Patients suffering from this disorder face an inhibited ability to produce hemoglobin, an essential protein in red blood cells that transports oxygen. The most severe […]
How a gene therapy cures infants with fatal genetic disease MLD
In groundbreaking medical news from the UK, a toddler suffering from a fatal genetic disorder known as metachromatic leukodystrophy (MLD) has been cured using a novel gene therapy. The treatment, termed Limeldy, while offering hope, comes with a hefty price tag and has sparked debates about newborn screening. Understanding MLD: MLD is a rare genetic […]
Astra strikes $1 billion gene therapy deal with Pfizer
In a monumental development for the pharmaceutical industry, AstraZeneca Plc has confirmed its decision to purchase a collection of rare disease gene therapies from the pharmaceutical giant, Pfizer Inc. This acquisition follows AstraZeneca’s impressive sales and profit in Q2, surpassing industry analysts’ projections. Details of the Deal: The partnership with Pfizer, as revealed on Friday, […]
Albumedix enters into collaboration agreement with Cell and Gene Therapy Catapult
Albumedix Ltd., a global frontrunner in recombinant human albumin (rAlb) and a catalyst for advanced therapies, has publicized a collaboration with Cell and Gene Therapy Catapult (CGT Catapult). This partnership aims to explore the potential of Albumedix’s signature albumin-based solutions in advanced therapy applications, specifically in the realm of viral vectors manufacturing. Significance of the […]
Prime Minister of the Republic of Serbia Visits SK bioscience to Establish Partnership for Vaccine Localization
Prime Minister Ana Brnabić of Serbia made a historic visit to the headquarters of SK bioscience, a pioneering vaccine and biotech company dedicated to enhancing human health. During her visit, an important memorandum of understanding (MOU) was signed between SK bioscience, the Serbian government, and Frontier Biopharma, with the goal of bolstering vaccine manufacturing in […]
Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine
Pfizer and BioNTech have received approval from the U.S. Food and Drug Administration (FDA) for their 2023-2024 COVID-19 vaccine, which is tailored to target the SARS-CoV-2 XBB.1.5 sublineage. This vaccine is designed to be administered as a single dose for most individuals aged 5 and older. Pre-clinical data indicates that this updated COVID-19 vaccine produces […]
CEPI partners with University of California, Davis to advance a vaccine against potentially deadly Rift Valley fever virus into clinical trials
In a significant stride towards preventing the deadly Rift Valley fever (RVF), CEPI (Coalition for Epidemic Preparedness Innovations) has joined forces with the University of California, Davis (UC Davis). Their mission: to advance a novel vaccine into clinical trials in Tanzania, a nation where RVF poses a severe threat to rural communities. CEPI will contribute […]
Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19
The European Medicines Agency (EMA) has now validated their marketing authorization application, marking a crucial step forward in their journey towards obtaining approval in Europe. This approval decision by the European Commission is anticipated to come to fruition in 2024. What makes this announcement particularly noteworthy are the compelling Phase 3 clinical results that underpin […]
Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture antibody cancer drug substance
Excerpt Samsung Biologics and Bristol Myers Squibb have expanded their strategic relationship with a new agreement focused on large-scale manufacturing of BMS’ commercial antibody cancer drug substance. Samsung Biologics’ advanced biomanufacturing facilities, including Plant 4 and the upcoming Plant 5, showcase their commitment to innovation, capacity, and delivering high-quality pharmaceuticals to patients around the world. […]
Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius’ novel anti-PD-1 mAb HANSIZHUANG in MENA
Excerpt Shanghai Henlius Biotech has entered an exclusive licensing agreement with PT Kalbe Genexine Biologics for the development and commercialization of HANSIZHUANG in 12 MENA countries, including Saudi Arabia, Egypt, and the UAE. This agreement involves upfront payments, regulatory milestones, and potential sales milestones. HANSIZHUANG, an anti-PD-1 therapy, has been approved for multiple indications in […]
Astrea Bioseparations expands manufacturing and warehousing capacity to support growing demand for its chromatography solutions in North America
Excerpt Astrea Bioseparations is expanding its manufacturing and warehousing capabilities in the US, driven by growing demand for its chromatography solutions in North America. The new 12,000 sq. ft. facility in Canton, Massachusetts, will support faster product delivery with record lead times and increase workforce capacity by up to 9%. This expansion enhances Astrea […]
Merck’s ERVEBO Vaccine Now Approved for Children to Combat Zaire Ebolavirus Disease
In a significant development in the realm of public health protection, Merck, known as MSD outside of the United States and Canada, has announced the expansion of ERVEBO’s indication. The U.S. Food and Drug Administration (FDA) has granted approval for the usage of ERVEBO in preventing disease caused by Zaire ebolavirus in individuals as young […]
Explore IMAPAC
Events
Thought leadership, industry knowledge-sharing and quality networking are at the core of IMAPAC's B2B events.
Intelligence
In-depth biopharmaceutical industry intelligence brought to you by our team of analysts.
LeadGen 360
Expand your influence, be it through branding & display ads, content creation or thought leadership.
Community
Linking professionals and fostering conversations among the biopharmaceutical industry professionals.
